Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Alejandro González Veliz: Ultrashort DAPT After PCI May Reduce Bleeding Without Increasing Overall Ischemic Events
Alejandro González Veliz/LinkedIn
Sep 23, 2026, 11:28

Alejandro González Veliz: Ultrashort DAPT After PCI May Reduce Bleeding Without Increasing Overall Ischemic Events

Alejandro González Veliz, Interventional Cardiologist at Institute of Cardiology and Cardiovascular Surgery, shared a post on LinkedIn about a recent article by Hendrianus H, et al., published in JACC: Cardiovascular Interventions, adding:

“How short is too short?

How long should dual antiplatelet therapy (DAPT) continue after PCI for acute coronary syndrome?

A new meta-analysis published in JACC: Cardiovascular Interventions evaluated 10 randomized trials involving 29,232 patients with ACS undergoing PCI, comparing ultrashort DAPT (1 month or less) with standard-duration DAPT (6–12 months).

The overall findings are interesting:

  • MACCE: HR 1.06 (95% CI 0.93–1.20) — no significant difference
  • Major bleeding: HR 0.47 (95% CI 0.35–0.64) — approximately 53% relative reduction
  • NACE: HR 0.83 (95% CI 0.72–0.97)

But there is an important nuance:

‘Ultrashort DAPT’ is not one single strategy.

When DAPT was abbreviated moderately — generally followed by potent P2Y12 inhibitor monotherapy — MACCE was not significantly different from standard-duration DAPT.

With more intensive abbreviation — including very early discontinuation or transition to clopidogrel/aspirin monotherapy — MACCE was higher:

HR 1.37 (95% CI 1.11–1.69).

The analysis also identified a signal that deserves attention in STEMI, where MACCE was higher with ultrashort DAPT (HR 1.41), although the interaction with NSTE-ACS was not statistically significant and the authors appropriately describe this finding as hypothesis-generating.

So the message is not simply:

‘Shorter DAPT is better.’

The more relevant question may be:

How short, in whom, and what comes next?

DAPT duration needs to be considered together with ischemic risk, bleeding risk, ACS phenotype, and the antiplatelet strategy used after DAPT.

The future of DAPT may be less about finding one universal duration — and more about precision and individualization.”

Title: Ultrashort vs Standard-Duration Dual Antiplatelet Therapy in Acute Coronary Syndrome Patients Undergoing PCI: A Meta-Analysis

Authors: Hendrianus Hendrianus, Diana A. Gorog, Udaya S. Tantry, Eliano P. Navarese, Sang Yeub Lee, Jun Hwan Cho, Jinhwan Jo, Jeonghoon Bae, Sam Yeol Ha, Satoshi Honda, Satoshi Yasuda, Bambang Widyantoro, Sunarya Soerianata, Paul A. Gurbel, Sang-Wook Kim, and Young-Hoon Jeong

Alejandro González Veliz: Ultrashort DAPT After PCI May Reduce Bleeding Without Increasing Overall Ischemic Events

Stay updated on all scientific advances with Hemostasis Today.

ACS Acute coronary syndrome Alejandro González Veliz and Young-Hoon Jeong Antiplatelet Therapy Bambang Widyantoro Bleeding Risk Cardiology Cardiovascular Medicine Coronary Intervention DAPT Diana A. Gorog Dual Antiplatelet Therapy Eliano P Navarese Hemostasis News Hemostasis Today Hendrianus Hendrianus ischemic risk Jeonghoon Bae Jinhwan Jo Jun Hwan Cho major bleeding NSTE-ACS P2Y12 Inhibitors Paul A. Gurbel PCI Precision Medicine Sam Yeol Ha Sang Yeub Lee Sang-Wook Kim Satoshi Honda Satoshi Yasuda STEMI Sunarya Soerianata Udaya S. Tantry
NewsFeed